Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer

May 29-June 2, 2015; Chicago, Illinois
Results of the first randomized, individualized therapy study in metastatic bladder cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 437 KB
Released: June 4, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options, M. Dror Michaelson, MD, PhD and Robert Motzer, MD highlight key data on the optimal use of immune checkpoint inhibitors for RCC

M. Dror Michaelson, MD, PhD Robert Motzer, MD Released: June 26, 2020

In this slideset from Clinical Care Options, Matt Milowsky, MD provides insights on treatment for patients with bladder cancer progressing after previous therapy.

Matthew I. Milowsky, MD Released: June 22, 2020

In this slideset from Clinical Care Options, Jonathan Rosenberg, MD provides insights on the latest data on managing patients with newly diagnosed bladder cancer.

Jonathan E. Rosenberg, MD Released: June 22, 2020

In this slideset from Clinical Care Options, Dan Petrylak, MD reviews the latest data on new approaches and novel agents for bladder cancer.

Daniel P. Petrylak, MD Released: June 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?